IGC Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IGC Pharma and other ETFs, options, and stocks.

About IGC

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. 

CEO
Ram Mukunda
CEORam Mukunda
Employees
70
Employees70
Headquarters
Potomac, Maryland
HeadquartersPotomac, Maryland
Founded
2005
Founded2005
Employees
70
Employees70

IGC Key Statistics

Market cap
31.28M
Market cap31.28M
Price-Earnings ratio
-4.32
Price-Earnings ratio-4.32
Dividend yield
Dividend yield
Average volume
805.87K
Average volume805.87K
High today
$0.36
High today$0.36
Low today
$0.3356
Low today$0.3356
Open price
$0.343
Open price$0.343
Volume
1.40M
Volume1.40M
52 Week high
$0.4985
52 Week high$0.4985
52 Week low
$0.2525
52 Week low$0.2525

Stock Snapshot

IGC Pharma(IGC) stock is priced at $0.34, giving the company a market capitalization of 31.28M. It carries a P/E multiple of -4.32.

On 2025-12-17, IGC Pharma(IGC) stock traded between a low of $0.34 and a high of $0.36. Shares are currently priced at $0.34, which is +0.4% above the low and -6.4% below the high.

The IGC Pharma(IGC)'s current trading volume is 1.4M, compared to an average daily volume of 805.87K.

During the past year, IGC Pharma(IGC) stock moved between $0.25 at its lowest and $0.50 at its peak.

During the past year, IGC Pharma(IGC) stock moved between $0.25 at its lowest and $0.50 at its peak.

IGC News

TipRanks 2d
IGC Pharma Increases Authorized Shares to 600 Million

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...

TipRanks 2d
IGC Pharma comments on potential reclassification of cannabis

The company said, “Recent reports indicating a possible shift in federal scheduling have coincided with renewed market interest across the cannabinoid landscape...

People also own

Based on the portfolios of people who own IGC. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.